CN110709398A - 氘代丁苯那嗪的类似物、其制备方法及用途 - Google Patents

氘代丁苯那嗪的类似物、其制备方法及用途 Download PDF

Info

Publication number
CN110709398A
CN110709398A CN201880018609.8A CN201880018609A CN110709398A CN 110709398 A CN110709398 A CN 110709398A CN 201880018609 A CN201880018609 A CN 201880018609A CN 110709398 A CN110709398 A CN 110709398A
Authority
CN
China
Prior art keywords
compound
deuterated tetrabenazine
pharmaceutical composition
tetrabenazine
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880018609.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·张
吉姆·克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospex Pharmaceuticals
Original Assignee
Ospex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61873991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110709398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ospex Pharmaceuticals filed Critical Ospex Pharmaceuticals
Publication of CN110709398A publication Critical patent/CN110709398A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CN201880018609.8A 2017-03-15 2018-03-15 氘代丁苯那嗪的类似物、其制备方法及用途 Pending CN110709398A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
US62/471,484 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
CN110709398A true CN110709398A (zh) 2020-01-17

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018609.8A Pending CN110709398A (zh) 2017-03-15 2018-03-15 氘代丁苯那嗪的类似物、其制备方法及用途

Country Status (20)

Country Link
US (5) US11813232B2 (cg-RX-API-DMAC10.html)
EP (1) EP3596077A1 (cg-RX-API-DMAC10.html)
JP (3) JP7608050B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200003791A (cg-RX-API-DMAC10.html)
CN (1) CN110709398A (cg-RX-API-DMAC10.html)
AR (1) AR111182A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018236336B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019018966A2 (cg-RX-API-DMAC10.html)
CA (1) CA3056612A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019002629A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019011271A2 (cg-RX-API-DMAC10.html)
EA (1) EA201992168A1 (cg-RX-API-DMAC10.html)
IL (1) IL269132A (cg-RX-API-DMAC10.html)
MX (1) MX2019010913A (cg-RX-API-DMAC10.html)
PE (1) PE20191819A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201908477QA (cg-RX-API-DMAC10.html)
TW (1) TWI772382B (cg-RX-API-DMAC10.html)
UA (1) UA127052C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018170214A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201906326B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
CN115916154A (zh) * 2020-06-10 2023-04-04 奥斯佩克斯医药公司 包括氘代丁苯那嗪的渗透剂型及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186848A (zh) * 2008-09-18 2011-09-14 奥斯拜客斯制药有限公司 囊泡单胺转运体2的苯并喹啉抑制剂
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186848A (zh) * 2008-09-18 2011-09-14 奥斯拜客斯制药有限公司 囊泡单胺转运体2的苯并喹啉抑制剂
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Also Published As

Publication number Publication date
NZ757789A (en) 2024-08-30
JP2020510073A (ja) 2020-04-02
JP2024050724A (ja) 2024-04-10
BR112019018966A2 (pt) 2020-04-22
JP7608050B2 (ja) 2025-01-06
US20220088006A1 (en) 2022-03-24
JP2023010754A (ja) 2023-01-20
CA3056612A1 (en) 2018-09-20
IL269132A (en) 2019-11-28
US11813232B2 (en) 2023-11-14
US12502385B2 (en) 2025-12-23
US20200016148A1 (en) 2020-01-16
EP3596077A1 (en) 2020-01-22
PE20191819A1 (es) 2019-12-27
JP7631572B2 (ja) 2025-02-18
WO2018170214A1 (en) 2018-09-20
TWI772382B (zh) 2022-08-01
UA127052C2 (uk) 2023-03-29
AR111182A1 (es) 2019-06-12
AU2018236336B2 (en) 2022-02-24
US20260144785A1 (en) 2026-05-28
TW201840317A (zh) 2018-11-16
MX2019010913A (es) 2020-01-20
CO2019011271A2 (es) 2020-02-28
KR20230003308A (ko) 2023-01-05
EA201992168A1 (ru) 2020-03-16
KR20200003791A (ko) 2020-01-10
US20220040170A1 (en) 2022-02-10
AU2022203369A1 (en) 2022-06-09
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
US20180263972A1 (en) 2018-09-20
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21
US11179386B2 (en) 2021-11-23
AU2022203369B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
JP7631572B2 (ja) デューテトラベナジンの類似体、その調製及び使用
US9339469B2 (en) R(+)-N-methyl-propargyl-aminoindan
JP2014534195A (ja) ラサギリンシトルアミド
WO2021150885A1 (en) Cannabinoid derivatives
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
CN116209673A (zh) 用于治疗sars的化合物
CN108101910B (zh) 一种N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
EP3985009B1 (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
NZ577311A (en) The oxalate salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
HK40018479A (en) Analogs of deutetrabenazine, their preparation and use
EA044519B1 (ru) Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством
HK40072843A (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
HK40072843B (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
CN106397411B (zh) 5-羟色胺受体激动剂及其制备方法和用途
CN105585576A (zh) 银杏内酯k晶l型及制备方法和其组合物与用途
JPH03264529A (ja) 鎮痛剤
HK1195551A (en) 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]]amino-1-naphthol, and preparing method and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018479

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Pasipani, NJ, USA

Applicant after: Ospex Pharmaceutical Co.,Ltd.

Address before: Pennsylvania, USA

Applicant before: Ospex pharmaceuticals

Country or region before: U.S.A.